Shots:

• The two companies will work together to research- discover- and develop therapeutic options related to the deficiency of the protein GBA which is a gene linked to Gaucher disease
• The collaboration will combine Evotec’s iPSC platform and drug discovery and development capabilities with Centogene’s global rare disease platform- including iPSC lines
• The collaboration follows the companies 2018 agreement to discover and develop novel small molecules in rare hereditary metabolic diseases

­ Ref: Evotec | Image: Wikipedia